Torque3
Torque3 is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Torque3.
Torque3 is a company.
Key people at Torque3.
Torque3 is a neurorehabilitation company developing an advanced platform that combines immersive simulations, robotic assistance, and task-oriented therapy to enhance recovery outcomes for stroke survivors and other neurological conditions like traumatic brain injuries (TBI), dementia, and Parkinson's disease[1][2][3][5]. The Torque3 platform (TOT+) targets plateaued patients in partner clinics, delivering equipment sales, licensing, and management fees while generating real-time data for progress tracking and neuroplasticity enhancement; it has secured initial clinic deals projecting over $2.5 million in revenue this year and $25 million over three years[1][2][3]. Serving stroke survivors primarily in the US via a network of 16-20 partner clinics (each needing ~120 patients annually), it solves suboptimal recovery rates by creating an "illusion of presence" and "perception of risk" through multi-sensory engagement, with early testing showing significantly better outcomes and a path to insurance reimbursement via new CPT codes[1][2][3][5].
Torque3 emerged from decades of research on immersive stimulation and robotics for stroke recovery, with the company leveraging this foundation for a "uncompromising" platform design[3][5]. Founded by a CEO who is a veteran of three prior ventures, the team includes executive board members and medical advisors with commercialization expertise; the founder leads efforts to ramp up production and clinic partnerships[1][2]. Key early traction includes securing the first two partner clinics (driving >$2.5M revenue this year), closing more deals imminently, and raising $5.54M across five rounds, culminating in a $3.15M Seed VC-II on December 9, 2022; headquartered in San Jose, CA (with ties to Utah), it's now filing additional patents and bridging to Series A[2][3][4][7].
Torque3 rides the wave of neurotech and rehab robotics, capitalizing on 30+ years of research proving immersive, multi-sensory therapy boosts neuroplasticity amid rising stroke/TBI incidence (e.g., millions affected yearly in the US)[3][5]. Timing aligns with maturing robotics (lower costs, better AI integration) and post-pandemic demand for outpatient neurorehab, where traditional therapy plateaus quickly; market forces like aging populations and insurance pushes for efficacy data favor its data-driven, objective platform[1][2][3]. It influences the ecosystem by pioneering private-pay clinics as a reimbursement bridge, potentially standardizing TOT+ and enabling exits/acquisitions in a sector seeing consolidation (e.g., by medtech giants)[2].
Torque3 is poised for Series A this year after its $500K bridge funding, with 16+ clinics, $25M three-year revenue, and CPT code pursuit triggering acquisition liquidity[1][2]. Trends like AI-enhanced neuroplasticity, VR/AR rehab adoption, and value-based care will accelerate growth, evolving its influence from niche innovator to ecosystem standard-setter in stroke/TBI recovery. As clinic data builds brand and validates outcomes, expect scaled impact beyond US stroke survivors, cementing its breakthrough in a high-need medtech frontier.
Key people at Torque3.
